173 related articles for article (PubMed ID: 28700521)
21. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I.
Staatz CE; Goodman LK; Tett SE
Clin Pharmacokinet; 2010 Mar; 49(3):141-75. PubMed ID: 20170205
[TBL] [Abstract][Full Text] [Related]
22. Effects of genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 on cyclosporine pharmacokinetics after renal transplantation.
Hu YF; Qiu W; Liu ZQ; Zhu LJ; Liu ZQ; Tu JH; Wang D; Li Z; He J; Zhong GP; Zhou G; Zhou HH
Clin Exp Pharmacol Physiol; 2006 Nov; 33(11):1093-8. PubMed ID: 17042920
[TBL] [Abstract][Full Text] [Related]
23. CYP3A7, CYP3A4, and CYP3A5 genetic polymorphisms in recipients rather than donors influence tacrolimus concentrations in the early stages after liver transplantation.
Dong Y; Xu Q; Li R; Tao Y; Zhang Q; Li J; Ma Z; Shen C; Zhong M; Wang Z; Qiu X
Gene; 2022 Jan; 809():146007. PubMed ID: 34688813
[TBL] [Abstract][Full Text] [Related]
24. Association Between CYP3A4 and CYP3A5 Genotypes and Cyclosporine's Blood Levels and Doses among Jordanian Kidney Transplanted Patients.
El-Shair S; Al Shhab M; Zayed K; Alsmady M; Zihlif M
Curr Drug Metab; 2019; 20(8):682-694. PubMed ID: 31385766
[TBL] [Abstract][Full Text] [Related]
25. The impact of CYP3A5*3 polymorphism on sirolimus pharmacokinetics: insights from predictions with a physiologically-based pharmacokinetic model.
Emoto C; Fukuda T; Venkatasubramanian R; Vinks AA
Br J Clin Pharmacol; 2015 Dec; 80(6):1438-46. PubMed ID: 26256674
[TBL] [Abstract][Full Text] [Related]
26. Influence of cytochrome P450 (CYP) 3A4*1G polymorphism on the pharmacokinetics of tacrolimus, probability of acute cellular rejection, and mRNA expression level of CYP3A5 rather than CYP3A4 in living-donor liver transplant patients.
Uesugi M; Hosokawa M; Shinke H; Hashimoto E; Takahashi T; Kawai T; Matsubara K; Ogawa K; Fujimoto Y; Okamoto S; Kaido T; Uemoto S; Masuda S
Biol Pharm Bull; 2013; 36(11):1814-21. PubMed ID: 24189425
[TBL] [Abstract][Full Text] [Related]
27. The effect of CYP3A4*1G allele on the pharmacokinetics of atorvastatin in Chinese Han patients with coronary heart disease.
He BX; Shi L; Qiu J; Zeng XH; Zhao SJ
J Clin Pharmacol; 2014 Apr; 54(4):462-7. PubMed ID: 24214373
[TBL] [Abstract][Full Text] [Related]
28. ABCB1 haplotype influences the sirolimus dose requirements in Chinese renal transplant recipients.
Lee J; Huang H; Chen Y; Lu X
Biopharm Drug Dispos; 2014 Apr; 35(3):164-72. PubMed ID: 24285256
[TBL] [Abstract][Full Text] [Related]
29. CYP3A4*1G and CYP3A5*3 genetic polymorphisms alter the antihypertensive efficacy of amlodipine in patients with hypertension following renal transplantation
.
Huang Y; Wen G; Lu Y; Wen J; Ji Y; Xing X; Li Y; Wen J; Yuan H
Int J Clin Pharmacol Ther; 2017 Feb; 55(2):109-118. PubMed ID: 27841150
[TBL] [Abstract][Full Text] [Related]
30. CYP3A5 but not CYP2D6 polymorphism contributes significantly to the variability in dextropropoxyphene disposition.
Yin OQ; Tomlinson B; Chow MS
J Clin Pharmacol; 2010 Oct; 50(10):1136-41. PubMed ID: 20133509
[TBL] [Abstract][Full Text] [Related]
31. Impact of the CYP3A5, CYP3A4, COMT, IL-10 and POR genetic polymorphisms on tacrolimus metabolism in Chinese renal transplant recipients.
Li CJ; Li L; Lin L; Jiang HX; Zhong ZY; Li WM; Zhang YJ; Zheng P; Tan XH; Zhou L
PLoS One; 2014; 9(1):e86206. PubMed ID: 24465960
[TBL] [Abstract][Full Text] [Related]
32. Effect of genetic polymorphisms on the pharmacokinetics of gefitinib in healthy Chinese volunteers.
Chen YR; Yu X; Xu LM; Mei J; Tian ML; Xu M; Jin QY; Ye LB; Yang SX
Xenobiotica; 2024 Jan; 54(1):38-44. PubMed ID: 38085693
[TBL] [Abstract][Full Text] [Related]
33. The influence of UGT2B7, UGT1A8, MDR1, ALDH, ADH, CYP3A4 and CYP3A5 genetic polymorphisms on the pharmacokinetics of silodosin in healthy Chinese volunteers.
Wang Z; Xiang Q; Cui Y; Zhao X; Zhou Y
Drug Metab Pharmacokinet; 2013; 28(3):239-43. PubMed ID: 23257391
[TBL] [Abstract][Full Text] [Related]
34. Simvastatin pharmacokinetics in healthy Chinese subjects and its relations with CYP2C9, CYP3A5, ABCB1, ABCG2 and SLCO1B1 polymorphisms.
Zhou Q; Ruan ZR; Jiang B; Yuan H; Zeng S
Pharmazie; 2013 Feb; 68(2):124-8. PubMed ID: 23469684
[TBL] [Abstract][Full Text] [Related]
35. Effect of
Liu S; Shi X; Tian X; Zhang X; Sun Z; Miao L
Front Pharmacol; 2017; 8():176. PubMed ID: 28408884
[TBL] [Abstract][Full Text] [Related]
36. Influence of CYP3A5 and MDR1(ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in Chinese renal transplant recipients.
Rong G; Jing L; Deng-Qing L; Hong-Shan Z; Shai-Hong Z; Xin-Min N
Transplant Proc; 2010 Nov; 42(9):3455-8. PubMed ID: 21094796
[TBL] [Abstract][Full Text] [Related]
37. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus.
Hesselink DA; van Schaik RH; van der Heiden IP; van der Werf M; Gregoor PJ; Lindemans J; Weimar W; van Gelder T
Clin Pharmacol Ther; 2003 Sep; 74(3):245-54. PubMed ID: 12966368
[TBL] [Abstract][Full Text] [Related]
38. CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients.
Le Meur Y; Djebli N; Szelag JC; Hoizey G; Toupance O; Rérolle JP; Marquet P
Clin Pharmacol Ther; 2006 Jul; 80(1):51-60. PubMed ID: 16815317
[TBL] [Abstract][Full Text] [Related]
39. CYP3A4 genetic polymorphisms predict cyclosporine-related clinical events in Chinese renal transplant recipients.
Wang YY; Zhang M; Lu FM; Jiao Z; Qiu XY
Chin Med J (Engl); 2012 Dec; 125(23):4233-8. PubMed ID: 23217392
[TBL] [Abstract][Full Text] [Related]
40. Impact of
Huang L; Wang J; Yang J; Zhang H; Ni Y; Zhu Z; Wang H; Gao P; Wu Y; Mao J; Fang L
Pharmacogenomics; 2019 Oct; 20(15):1071-1083. PubMed ID: 31588879
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
